Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections.
Koselj
M
M
Department of Nephrology, University Medical Centre, Ljubljana, Slovenia.
Bren
A
A
Kandus
A
A
Kovac
D
D
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D001393:Azoles / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004347:Drug Interactions; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D007877:Legionnaires' Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy*; D011183:Postoperative Complications; D012293:Rifampin / Q000627:therapeutic use*; D013290:Streptococcal Infections / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000935:Antifungal Agents; D001393:Azoles; D004917:Erythromycin; D016572:Cyclosporine; D012293:Rifampin